Research programme: Duchenne muscular dystrophy therapeutics - Genethon

Drug Profile

Research programme: Duchenne muscular dystrophy therapeutics - Genethon

Alternative Names: micro-dystrophin program - Genethon

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genethon
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 14 Jun 2018 Sarepta Therapeutics enters into a manufacturing agreement with Brammer Bio for its micro-dystrophin Duchenne muscular dystrophy and Limb girdle muscular dystrophy gene therapy programs
  • 27 Jul 2017 Pharmacodynamics data from a preclinical trial in Duchenne muscular dystrophy released by Sarepta Therapeutics
  • 21 Jun 2017 Genethon and Sarepta Therapeutics enter an option agreement for Duchenne muscular dystrophy therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top